Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders

Executive Summary

• Marvel Biosciences Corp. received advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop a pediatric‑friendly liquid formulation of its lead compound MB‑204.
• The project targets children and adolescents with neurodevelopmental disorders such as autism spectrum disorder, Rett syndrome, and Fragile X syndrome, aiming to create a small‑volume oral dosage suitable for syringes or feeding tubes.
• Funding supports collaboration with Canadian research partners, keeping high‑value pharmaceutical R&D in Canada and generating data for future pediatric clinical trials and regulatory submissions.

Key Details

• Funding Source: NRC IRAP (Industrial Research Assistance Program).
• Purpose: Development of a pediatric oral liquid formulation of MB‑204 to address swallowing challenges in neurodevelopmental disorder patients.
• Target Indications: Autism spectrum disorder, Rett syndrome, Fragile X syndrome, and other neurodevelopmental conditions.
• Formulation Goals: Small‑volume (oral syringe or feeding tube), stable, reproducible dosing without compromising drug exposure or consistency.
• Project Activities: Evaluation of multiple liquid formulation approaches; partnership with Canadian research institutions and service providers.
• Strategic Fit: Aligns with Marvel’s broader strategy to expand its IP portfolio and advance patient‑centric therapies for neurological and neurodevelopmental diseases.
• Lead Compound Background: MB‑204 is a fluorinated derivative of Istradefylline, an approved Parkinson’s drug and the only adenosine A2A receptor blocker on the market; preclinical validation already completed.

Notable Quotes

“Developing medicines that children can actually take is a very important, yet many times an overlooked part of drug development,” said Rod Matheson, CEO at Marvel Biosciences.
“This support will allow us to directly address a clinical barrier faced by patients and caregivers and prepare MB‑204 dosing to be aligned with future pediatric clinical development.”